User:Bailey Dove/Sandbox1
From Proteopedia
(Difference between revisions)
| Line 23: | Line 23: | ||
<ref>Centers for Disease Control and Prevention. (2015). Viral hepatitis - hepatitis C information. Retrieved from http://www.cdc.gov/hepatitis/hcv/index.htm</ref> | <ref>Centers for Disease Control and Prevention. (2015). Viral hepatitis - hepatitis C information. Retrieved from http://www.cdc.gov/hepatitis/hcv/index.htm</ref> | ||
<ref>PMID: 21250386</ref> | <ref>PMID: 21250386</ref> | ||
| - | < | + | <ref>Merck & Co., Inc. (n.d.) Highlights of prescribing information. Retrieved from https://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf</ref> |
Revision as of 21:18, 11 November 2016
Hepatitis C
The Hepatitis C virus (HCV) is a blood-borne, single stranded RNA virus. [1] The genome of HCV encodes a polyprotein precursor of approximatley 3,000 amino acids, which are cleaved into 1 proteins by various proteases, one of which is the NS3 serine protease. [2]
Victrelis
Victrelis (boceprevir) is an antiviral Hepatitis C medication approved by the United States Food and Drug Administration in 2011. Victrelis is an inhibitor of the non-structural protein 3 (NS3) serine protease. The medication inhibits viral replication in Hepatitis C virus infected cells.[3]
| |||||||||||
References
- ↑ Centers for Disease Control and Prevention. (2015). Viral hepatitis - hepatitis C information. Retrieved from http://www.cdc.gov/hepatitis/hcv/index.htm
- ↑ Lin C. HCV NS3-4A Serine Protease PMID:21250386
- ↑ Merck & Co., Inc. (n.d.) Highlights of prescribing information. Retrieved from https://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf
- ↑ Merck & Co., Inc. (n.d.) Highlights of prescribing information. Retrieved from https://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf
